With an FDA approval in hand, ADC Therapeutics has enlisted its old friend Avid Bioservices to rev up commercial manufacturing for its new drug Zynlonta.  ...

AstraZeneca investors breathed a sigh of relief last month when the U.S. antitrust watchdog cleared the company’s proposed $39 billion acquisition of Alexion Pharma....

As Moderna's COVID-19 vaccine rolls out across the globe, the mRNA specialist has continued to bolster its production network. With a deal unveiled over th...

The new chief medical officer at Guardant Health is taking a step back—a step back in the typical cancer journey, that is, moving to diagnostics from oncology d...

After back-to-back losses in court, Novartis’ generics outfit Sandoz had hoped the U.S. Supreme Court would take up its long shot biosimilars case against ...

Regeneron’s new med Evkeeza already sports an approval in the ultra-rare disease homozygous familial hypercholesterolemia, which is associated with extreme levels of...

With an approval filing already on the FDA’s docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in a...

As doctors faced the novel coronavirus without an arsenal early last year, AstraZeneca wondered whether its diabetes drug Farxiga could help prevent organ ...

Novartis had hoped Entresto could find itself yet another niche, this time in patients who’d had a heart attack. But in late April, a large study found the...

More than a year after Apellis Pharmaceuticals proved its C3 inhibitor pegcetacoplan could go head-to-head with industry heavyweight Soliris in patients with th...